Biomarin’s drug wins Europe’s first approval for type of dwarfism
August 27, 2021; 10:07 AM EDT
Biomarin said on Friday France had granted Voxzogo a temporary authorization for use allowing immediate access to the drug in the country.
The drug would cost roughly $300,000 per patient annually in France, excluding discounts, and Biomarin said it expects the list price in Germany to be consistent with that in France.
Analysts expect the drug to bring in sales of more than $750 million by 2027, according to Refinitiv data.
Achondroplasia, a form of disproportionate short stature caused by a mutation in a gene that regulates bone growth, occurs in about one in 25,000 newborns. Complications from the condition can even result in a spinal decompression surgery.